This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 Nov 1;26(31):5014-7.

doi: 10.1200/JCO.2008.18.1081. Epub 2008 Sep 22.

Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

Benjamin Besse, Thierry Le Chevalier

PMID: 18809602
DOI: 10.1200/JCO.2008.18.1081

Editorial

Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?

Benjamin Besse et al. J Clin Oncol. 2008.

. 2008 Nov 1;26(31):5014-7.

doi: 10.1200/JCO.2008.18.1081. Epub 2008 Sep 22.

Authors

Benjamin Besse, Thierry Le Chevalier

PMID: 18809602
DOI: 10.1200/JCO.2008.18.1081

No abstract available

PubMed Disclaimer

Comment on

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups.
Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR. Strauss GM, et al. J Clin Oncol. 2008 Nov 1;26(31):5043-51. doi: 10.1200/JCO.2008.16.4855. Epub 2008 Sep 22. J Clin Oncol. 2008. PMID: 18809614 Free PMC article. Clinical Trial.

Similar articles

Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H. Azuma K, et al. Lung Cancer. 2009 Jun;64(3):326-33. doi: 10.1016/j.lungcan.2008.09.002. Epub 2008 Nov 1. Lung Cancer. 2009. PMID: 18977553
[Adjuvant chemotherapy in the early stages of non-small cell bronchial cancers].
Le Chevalier T. Le Chevalier T. Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S31-2. Rev Pneumol Clin. 2002. PMID: 12538932 French. No abstract available.
Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.
Socinski MA, Detterbeck FC, Rivera MP, Egan TM, Halle J, Rosenman J. Socinski MA, et al. N C Med J. 1996 Sep-Oct;57(5):281-6. N C Med J. 1996. PMID: 8854691 Review. No abstract available.
[Radio-chemotherapy combination in locally advanced, inoperable, non-small cell bronchial cancers].
Mornex F. Mornex F. Rev Pneumol Clin. 2002 Nov;58(5 Pt 2):3S37-41. Rev Pneumol Clin. 2002. PMID: 12538934 French. No abstract available.
[Clinical advances in the chemotherapy of non-small cell lung cancer].
Liao ML, Cheng BJ. Liao ML, et al. Zhonghua Jie He He Hu Xi Za Zhi. 2004 Jul;27(7):480-2. Zhonghua Jie He He Hu Xi Za Zhi. 2004. PMID: 15312563 Review. Chinese. No abstract available.

See all similar articles

Cited by

Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, Miller VA. Oxnard GR, et al. Clin Cancer Res. 2011 Oct 1;17(19):6322-8. doi: 10.1158/1078-0432.CCR-11-1080. Epub 2011 Aug 10. Clin Cancer Res. 2011. PMID: 21831955 Free PMC article.
HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.
Zhang J, Chen N, Qi J, Zhou B, Qiu X. Zhang J, et al. J Cancer Res Clin Oncol. 2014 Aug;140(8):1441-9. doi: 10.1007/s00432-014-1687-2. Epub 2014 Apr 27. J Cancer Res Clin Oncol. 2014. PMID: 24770635 Free PMC article.
Efficacy of Platinum-Based Adjuvant Chemotherapy on Prognosis of Pathological Stage II/III Lung Adenocarcinoma based on EGFR Mutation Status: A Propensity Score Matching Analysis.
Isaka T, Ito H, Nakayama H, Yokose T, Katayama K, Yamada K, Masuda M. Isaka T, et al. Mol Diagn Ther. 2019 Oct;23(5):657-665. doi: 10.1007/s40291-019-00419-9. Mol Diagn Ther. 2019. PMID: 31347029
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.
Bonomi M, Pilotto S, Milella M, Massari F, Cingarlini S, Brunelli M, Chilosi M, Tortora G, Bria E. Bonomi M, et al. J Exp Clin Cancer Res. 2011 Dec 29;30(1):115. doi: 10.1186/1756-9966-30-115. J Exp Clin Cancer Res. 2011. PMID: 22206620 Free PMC article. Review.
Alectinib impressively enters the adjuvant setting for early-stage ALK-rearranged non-small cell lung cancer and outperforms chemotherapy-let's define who benefits the most.
Santoni-Rugiu E, Sørensen JB, Urbanska EM. Santoni-Rugiu E, et al. Transl Lung Cancer Res. 2025 Feb 28;14(2):310-313. doi: 10.21037/tlcr-24-961. Epub 2025 Feb 21. Transl Lung Cancer Res. 2025. PMID: 40114944 Free PMC article. No abstract available.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information